mp.weixin.qq.com·· 12 hours agoPickScore82
AstraZeneca Announces US Approval of Sunvozertinib (ZEGFROVY) for EGFR exon20ins NSCLC
In brief
On October 23, 2026, AstraZeneca announced that ZEGFROVY (sunvozertinib tablets), independently developed by Dizhe Pharmaceutical, is officially launched in the United States. The drug treats adults with locally advanced or metastatic NSCLC with confirmed EGFR exon20ins whose disease progressed on or who cannot tolerate prior platinum-based chemotherapy.
Why it matters
Dual China-US approval, guideline recommendation and reimbursement access offer a direct reference for positioning this oral targeted drug.
Source: mp.weixin.qq.com · mp.weixin.qq.com